A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers

被引：0
|
作者：
Donghoon Shin
Yoon Jung Lee
Jihye Choi
Dahyoung Lee
Minjeong Park
Magdalena Petkova
机构：
[1] Samsung Bioepis Co.,Medical Affairs
[2] Ltd,Clinical Development
[3] Samsung Bioepis Co.,Biometrics
[4] Ltd,Clinical Bioanalysis
[5] Samsung Bioepis Co.,Clinical Pharmacology Unit
[6] Ltd,undefined
[7] Samsung Bioepis Co.,undefined
[8] Ltd,undefined
[9] SGS LSS,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
SB8; Bevacizumab; Biosimilar; Pharmacokinetics; Immunogenicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：567 / 575
页数：8
相关论文
共 50 条
  • [1] A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
    Shin, Donghoon
    Lee, Yoon Jung
    Choi, Jihye
    Lee, Dahyoung
    Park, Minjeong
    Petkova, Magdalena
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (04) : 567 - 575
  • [2] A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
    Markus, Richard
    Chow, Vincent
    Pan, Zhiying
    Hanes, Vladimir
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (04) : 755 - 763
  • [3] A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers
    Eto, Takashi
    Karasuyama, Yuji
    Gonzalez, Veronica
    Del Campo Garcia, Ana
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (04) : 713 - 722
  • [4] A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
    Richard Markus
    Vincent Chow
    Zhiying Pan
    Vladimir Hanes
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 755 - 763
  • [5] A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers
    Takashi Eto
    Yuji Karasuyama
    Verónica González
    Ana Del Campo García
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 713 - 722
  • [6] A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers
    Wang, Jin
    Qi, Lu
    Liu, Long
    Wang, Zejuan
    Chen, Gang
    Wang, Yu
    Liu, Xiaona
    Liu, Ying
    Liu, Huijuan
    Tong, Yuanxu
    Liu, Chen
    Lei, Chunpu
    Wang, Xinghe
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [7] A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects
    Zhang, Hong
    Zhu, Xiaoxue
    Wei, Haijing
    Li, Cuiyun
    Chen, Hong
    Li, Xiaojiao
    Wu, Min
    Liu, Jingrui
    Chen, Guiling
    Zhou, Hui
    Zheng, Shirui
    Ding, Yanhua
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 57 (03) : 167 - 174
  • [8] A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers
    Knight, Beverly
    Rassam, Danielle
    Liao, Shanmei
    Ewesuedo, Reginald
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 839 - 846
  • [9] A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers
    Beverly Knight
    Danielle Rassam
    Shanmei Liao
    Reginald Ewesuedo
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 839 - 846
  • [10] Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab
    Park, Suemin
    Jung, Jin Ah
    Ju, Sungil
    Lim, Hyeong-Seok
    FRONTIERS IN PHARMACOLOGY, 2024, 14
12345